相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens
Noa Biran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
Cytogenetics of extramedullary manifestations in multiple myeloma
Lisa Billecke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases
Leo Rasche et al.
ANNALS OF HEMATOLOGY (2012)
Extramedullary involvement in multiple myeloma
Joan Blade et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma
Lijuan Chen et al.
CANCER LETTERS (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
M. Varettoni et al.
ANNALS OF ONCOLOGY (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
The impact of extramedullary disease at presentation on the outcome of myeloma
Ping Wu et al.
LEUKEMIA & LYMPHOMA (2009)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Bortezomib:: an effective agent in extramedullary disease in multiple myeloma
R Laura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect
E Paubelle et al.
LEUKEMIA (2005)
Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features
ABT Fassas et al.
LEUKEMIA & LYMPHOMA (2004)
Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
R Fonseca et al.
BLOOD (2002)
Thalidomide in multiple myeloma:: lack of response of soft-tissue plasmacytomas
J Bladé et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
